India Exchange Filings

Gujarat Themis Biosyn Investor Presentation: MBJ Acquisition and CDMO Strategy

Gujarat Themis Biosyn Ltd details ₹1,351 crore acquisition of Japan’s MicroBioPharm

  • MBJ reported FY26 revenue of ₹557 crore and EBITDA of ₹138 crore, a 25% margin.
  • Presentation also lists refinancing of MBJ’s existing ₹632 crore loan.
  • GTBL cited 990 KL fermentation capacity at its Vapi facility and plans to expand product, technology and geographic reach.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.